Yüksel Ürün: Lurbinectedin plus Atezolizumab Doubled PFS vs Atezolizumab Alone in IMforte Trial
Yüksel Ürün, Medical Oncology Professor at Ankara University School of Medicine, shared a post on X about a paper by Luis Paz-Ares et al. published in The Lancet:
“Breakthrough in extensive-stage small-cell lung cancer maintenance!
Lurbinectedin + Atezolizumab doubled PFS vs Atezolizumab alone!
OS benefit is also significant (13.2 vs 10.6 mo)
First phase 3 trial to improve both PFS and OS in 1L maintenance for ES-SCLC.”
Title: Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
Authors: Luis Paz-Ares, Hossein Borghaei, Stephen V. Liu, Solange Peters, Roy S. Herbst, Katarzyna Stencel, Margarita Majem, Mehmet Ali Nahit Şendur, Grzegorz Czyżewicz, Reyes Bernabé Caro, Ki Hyeong Lee, Melissa L. Johnson, Nuri Karadurmuş, Christian Grohé, Sofia Baka, Tibor Csőszi, Jin Seok Ahn, Raffaele Califano, Tsung-Ying Yang, Yasemin Kemal, Marcus Ballinger, Vaikunth Cuchelkar, Vilma Graupner, Ya-Chen Lin, Debasis Chakrabarti, Kamalnayan Bhatt, George Cai, Robert Iannone, Martin Reck
You can read the Full Article in The Lancet.
More posts featuring Yüksel Ürün.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023